Outcomes of EAM conditioned autologous haematopoietic SCT for lymphoma. A matched pairs retrospective single-centre study analysis

Loke, Justin; Ward, Janice; Mahendra, Premini; Chaganti, Sridhar; Malladi, Ram

doi:10.1038/bmt.2013.90

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of retrospective studies have tried to address the issue. Unfortunately, EAM conditioning in 12 Hodgkin's lymphoma and 11 non-Hodgkin's lymphoma patients by Loke et al [ 19 ] gave disappointing results (mOS 29 months compared to 77 months for the matched BEAM group). A more recent study by Bekadja et al [ 20 ] demonstrated comparable results in efficacy and toxicity with EAM, but the Ara-C total dose was 8 gr/m 2 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma

Pangarsa

Naibaho

Yunarvika

et al. 2021

Case Reports in Hematology

View full text Add to dashboard Cite

Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modified-BEAM conditioning regimen without BCNU consisting of etoposide, cytarabine, and melphalan (EAM) in a patient with relapsed Hodgkin’s lymphoma. Before transplantation, the patient achieved second complete remission (CR2) using brentuximab vedotin and ESHAP (BR-ESHAP) chemotherapy. The ASCT went well without significant complications. This case demonstrated the considerable efficacy of EAM protocol as a conditioning regimen in terms of sufficient ablative capabilities, and the patient showed a successful hematopoietic engraftment. Although durability of the disease-free survival needs further observation, it had nearly 18 months of complete remission and the patient was in good performance status at the time of writing this manuscript.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In this case report, we ablated the BCNU from the original BEAM regimen without altering either the dosage or drug sequence of the rest component, identical to Loke et al's protocol [ 19 ]. The details of our protocol can be found elsewhere [ 5 ].…”

Section: Discussionmentioning

confidence: 99%